This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: ( R )- N -(1-Methyl-2-hydroxyethyl)-13-( S )-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes

Title ( R )- N -(1-Methyl-2-hydroxyethyl)-13-( S )-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes
Abstract

The synthesis of potent metabolically stable endocannabinoids is challenging. Here we report a chiral arachidonoyl ethanolamide (AEA) analogue, namely, (13 S,1' R)-dimethylanandamide (AMG315, 3a), a high affinity ligand for the CB1 receptor ( K i of 7.8 ± 1.4 nM) that behaves as a potent CB1 agonist in vitro (EC 50 = 0.6 ± 0.2 nM). (13 S,1' R)-dimethylanandamide is the first potent AEA analogue with significant stability for all endocannabinoid hydrolyzing enzymes as well as the oxidative enzymes COX-2. When tested in vivo using the CFA-induced inflammatory pain model, 3a behaved as a more potent analgesic when compared to endogenous AEA or its hydrolytically stable analogue AM356. This novel analogue will serve as a very useful endocannabinoid probe.

Apa Reference Liu, Y., Ji, L., Eno, M., Kudalkar, S., Li, A., Schimpgen, M., Benchama, O., Morales, P., Xu, S., Hurst, D., Wu, S., Mohammad, K.A., Wood, J.T., Zvonok, N., Papahatjis, D.P., Zhou, H., Honrao, C., Mackie, K., Reggio, P., Hohmann, A.G., Marnett, L.J., Makriyannis, A. & Nikas, S.P. (2018). ( R )- N -(1-Methyl-2-hydroxyethyl)-13-( S )-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. Journal of Medicinal Chemistry, 61(19), 8639-8657. 10.1021/acs.jmedchem.8b00611
Doi 10.1021/acs.jmedchem.8b00611
Publication Date 10 Sep 2018
Publication Type Article
Researcher Paula Morales
Ontology Molecular Interactions/Docking
Research Groups
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home